---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-24-000046"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:12:28.054410+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allogene restructures JV; ownership diluted to 15.4%, license royalty amended to flat mid-single-digit

## Summary
- JV acquires Overland US (lead asset OL-101, autologous GPRC5D-BCMA CAR-T for multiple myeloma).
- Overland's ownership in JV increases to 69.63%; Allogene's drops to 15.37% after share incentive plan increase.
- Exclusive license royalty changed to flat mid single-digit on net sales in territory, no longer subject to reductions.
- Allogene gains termination rights for funding default or failure to initiate tech transfer; license auto-terminates if Allogene's ownership <7.5% unless mutual plan agreed.
- Overland distributes all JV shares to HH BioPharma Holdings (HBP), which gets 3 of 5 board seats.

## SEC filing metadata
- accession: 0001737287-24-000046
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000046/0001737287-24-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000046/allo-20240524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-24-000046
- JSON: https://secwatch.observer/filing/0001737287-24-000046.json
- Plain text: https://secwatch.observer/filing/0001737287-24-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.